Abstract
Background Hereditary ataxias are genetically diverse, yet up to 75% remain undiagnosed due to technological and financial barriers. A pathogenic ZFHX3 GGC repeat expansion was recently linked to spinocerebellar ataxia type 4 (SCA4), characterized by progressive ataxia and sensory neuropathy, with all reported cases in individuals of Northern European ancestry.
Methods We performed Oxford Nanopore Technologies (ONT) genome long-read sequencing (>115 GB per sample) on a total of 15 individuals from Chile; 14 patients with suspected hereditary movement disorders and one unrelated family member. Variants were identified using PEPPER-Margin-DeepVariant 0.8 (SNVs), Sniffles 2.4 (SVs), and Vamos 2.1.3 (STRs). Ancestry was inferred using GenoTools with reference data from the 1000 Genomes Project, Human Genome Diversity Project, and an Ashkenazi Jewish panel. Haplotype analysis was conducted by phasing SNVs within ZFHX3, and methylation profiling was performed with modbamtools.
Results We identified ZFHX3 GGC repeat expansions (47–55 repeats) in four individuals with progressive ataxia, polyneuropathy, and vermis atrophy. One case presented parkinsonism–ataxia, expanding the phenotype. Longer expansions correlated with earlier onset and greater severity. Hypermethylation was detected on the expanded allele, and haplotype analysis linked ultra-rare ZFHX3 variants to distant Swedish ancestry.
Conclusion This is the first report of SCA4 outside Northern Europe, confirming a shared founder haplotype and expansion instability. The presence of parkinsonism broadens the clinical spectrum. Comprehensive genetic testing across diverse populations is crucial, and long-read sequencing enhances diagnostic yield by detecting repeat expansions and SNVs in a single assay.
Competing Interest Statement
The authors declare that this work was supported in part by the Intramural Research Program of the National Institute on Aging (NIA) and the Center for Alzheimers and Related Dementias (CARD) within the Intramural Research Program of the NIA and the National Institute of Neurological Disorders and Stroke (ZIANS003154, ZIAAG000538, AG000538), National Institutes of Health (NIH), with computational resources provided by the NIH HPC Biowulf cluster. Authors affiliated with CARD or the Laboratory of Neurogenetics at NIH received funding from these institutions. D.E.M. holds stock in MyOme, serves on the advisory boards of Oxford Nanopore Technologies (ONT) and Basis Genetics, and has partnerships with ONT, Pacific Biosciences, and Basis Genetics. P.S.A. serves on an advisory board for Biogen. Several authors received grant support, including P.S.-A. (Michael J. Fox Foundation), S.B.G. (NIH 5T32HG000035-29), D.E.M. (NIH DP5OD033357), H.H. (Michael J. Fox Foundation, MRC, Wellcome Trust, NIHR UCL/UCLH BRC), and B.G. and M.J.P. (NIH R01HG011649).
Clinical Protocols
https://www.protocols.io/view/protocol-purification-of-dna-from-whole-blood-usin-c7ypzpvn
https://github.com/molleraj/CARDlongread-chile-data-processing
Funding Statement
This study was supported in part by the Intramural Research Program of the National Institute on Aging (NIA) and the Center for Alzheimers and Related Dementias (CARD), within the Intramural Research Program of the NIA and the National Institute of Neurological Disorders and Stroke (ZIANS003154, ZIAAG000538), National Institutes of Health (AG000538). Additional support was provided by the National Institutes of Health (DP5OD033357, R01HG011649, 5T32HG000035-29), as well as grants from the Michael J. Fox Foundation, the Medical Research Council, the Wellcome Trust, and the National Institute for Health and Care Research (UCL/UCLH Biomedical Research Centre)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Centro de Trastornos del Movimiento (CETRAM) gave ethical approval for this work. Written informed consent was obtained from all participants
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵The authors declare no financial or non-financial conflicts of interest related to this manuscript.
This study was supported in part by the Intramural Research Program of the National Institute on Aging (NIA) and the Center for Alzheimer’s and Related Dementias (CARD), within the Intramural Research Program of the NIA and the National Institute of Neurological Disorders and Stroke (ZIANS003154, ZIAAG000538), National Institutes of Health (AG000538).
Additional support was provided by the National Institutes of Health (DP5OD033357, R01HG011649, 5T32HG000035-29), as well as grants from the Michael J. Fox Foundation, the Medical Research Council, the Wellcome Trust, and the National Institute for Health and Care Research (UCL/UCLH Biomedical Research Centre).
